CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients

About this update from Cytosorbents Corporation

[{"type":"text","content":"MONMOUTH JUNCTION, N.J., Nov. 25, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the publication of the largest case series using CytoSorb in critically ill COVID-19 patients to date. \n\n \n \n \n \n \n \n\n \nIn a recent publication in the peer-reviewed journal, Artificial Organs, entitled, \"Continuous renal replacement therapy with the addition of CytoSorb® cartridge in critically ill patients with COVID-19 plus acute kidney injury: a case-series,\" Alharthy and colleagues report on the use of CytoSorb in all 50 critically ill COVID-19 patients that required renal replacement therapy for acute kidney injury at their institution during June and July of this year. \nOn ICU admission, the average age was 49.6 ± 8.9 years with a mean Acute Physiology and Chronic Health Evaluation II (APACHE 2) score of 22.5 ± 1.1, conferring a mortality risk of greater than 40% All of these patients were hyperinflamed and all had multiple organ failure including respiratory failure requiring mechanical ventilation, acute kidney injury requiring renal replacement therapy, and septic shock requiring the use of vasopressors. 24% (12/50) had documented pulmonary emboli, or blood clots in the lung, by CT scan, another independent mortality risk factor Patients were treated continuously with CytoSorb and continuous renal replacement therapy (CRRT), exchanging the CytoSorb cartridge every 24 hours, until the achievement of all of the following: normalization of oxygenation, reversal of shock without the need for vasopressors, and the absence of electrolyte and metabolic abnormalities In addition to CytoSorb, all patients received standard of care therapy including low tidal volume ventilation, prone positioning, antibiotics, steroids, and prophylactic anticoagulation, with empiric ribavirin and interferon beta-1b. In this retrospective case series, 28-day survival post-ICU admission was 70%. Survivors averaged 2 ± 1 CytoSorb treatments to achieve statistically significant improvements in a wide range of inflammatory and clinical parameters, compared to before CytoSorb treatment (p","length":4388,"tagName":"div"}]

More updates from Cytosorbents Corporation